Sarah Blagden
#144,960
Most Influential Person Now
British oncologist
Sarah Blagden's AcademicInfluence.com Rankings
Sarah Blagdenmedical Degrees
Medical
#3545
World Rank
#4019
Historical Rank
Oncology
#260
World Rank
#268
Historical Rank
Sarah Blagdenphilosophy Degrees
Philosophy
#11959
World Rank
#16543
Historical Rank
Logic
#8784
World Rank
#11037
Historical Rank
Download Badge
Medical Philosophy
Sarah Blagden's Degrees
- PhD Oncology University of Oxford
Why Is Sarah Blagden Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sarah Blagden is a Professor of Experimental Oncology at the University of Oxford. Her laboratory research is in investigating post-transcriptional mechanisms for ovarian cancer behavior. Her clinical research is in conducting early phase trials in novel cancer therapeutics for people with advanced malignancies.
Sarah Blagden's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
- Performance status score: do patients and their oncologists agree? (2003) (180)
- Polar expeditions — provisioning the centrosome for mitosis (2003) (148)
- Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies (2011) (139)
- The biological and therapeutic relevance of mRNA translation in cancer (2011) (135)
- La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs (2017) (127)
- Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. (2014) (123)
- The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer (2015) (119)
- LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression (2014) (109)
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial (2019) (109)
- The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration (2010) (105)
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. (2016) (96)
- The La-Related Proteins, a Family with Connections to Cancer (2015) (89)
- Drosophila Larp associates with poly(A)-binding protein and is required for male fertility and syncytial embryo development. (2009) (89)
- Drugging cell cycle kinases in cancer therapy. (2005) (88)
- A study of symptoms described by ovarian cancer survivors. (2012) (71)
- A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours (2007) (69)
- Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer (2009) (68)
- A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours (2008) (67)
- Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. (2011) (62)
- Making sense of antisense. (2005) (61)
- ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis (2017) (59)
- The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5′TOP sequence (2015) (58)
- Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer (2015) (58)
- A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours (2019) (48)
- Risk of Ovarian Cancer Relapse Score (2014) (45)
- A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 (2018) (41)
- The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours (2002) (41)
- Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer (2015) (40)
- Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells (2019) (38)
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer (2019) (36)
- First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer (2014) (35)
- An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials (2014) (34)
- Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer (2018) (32)
- A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours (2009) (31)
- A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. (2006) (30)
- Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. (2012) (30)
- Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study (2018) (30)
- Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer (2012) (30)
- Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation (2015) (28)
- Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies (2015) (28)
- Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. (2014) (26)
- Promising molecular targets in ovarian cancer (2009) (26)
- Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement (2020) (24)
- Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies (2005) (23)
- A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer. (2019) (19)
- A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours (2005) (19)
- Combining conventional therapy with immunotherapy: A risky business? (2019) (18)
- Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. (2009) (17)
- Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients (2002) (17)
- A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel Disease (2015) (16)
- A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer. (2019) (16)
- Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trials (2014) (15)
- A study to evaluate the cause of bone demineralization in gynecological cancer survivors. (2013) (15)
- A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol (2020) (14)
- Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. (2011) (14)
- Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial (2020) (14)
- The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction (2020) (13)
- Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. (2012) (13)
- The RNA binding protein Larp 1 regulates cell division , apoptosis and cell migration (2010) (12)
- Targeting cell cycle kinases and kinesins in anticancer drug development (2007) (12)
- Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies (2013) (11)
- Future directions in the management of epithelial ovarian cancer. (2008) (11)
- Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics (1999) (11)
- Docetaxel in the management of ovarian cancer (2005) (10)
- Ancient and modern: hints of a core post‐transcriptional network driving chemotherapy resistance in ovarian cancer (2017) (10)
- Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer (2013) (10)
- Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer (2011) (10)
- Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies. (2015) (9)
- NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials (2020) (9)
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response (2019) (9)
- The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer (2015) (9)
- Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer. (2012) (9)
- 3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer (2014) (8)
- The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers (2021) (8)
- A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors (2005) (8)
- A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. (2015) (7)
- 610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma (2012) (7)
- A source of hope for platinum-resistant ovarian cancer? (2021) (7)
- A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors. (2012) (6)
- Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival (2015) (6)
- Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response (2021) (6)
- ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors [Abstract] (2013) (6)
- Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival (2014) (5)
- A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers. (2015) (5)
- New challenges in psycho‐oncology: Using drug development methodology to improve survivorship and supportive care intervention trials (2019) (5)
- The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial (2021) (5)
- LARP1 isoform expression in human cancer cell lines (2020) (5)
- Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation (2019) (5)
- Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits (2019) (5)
- Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. (2016) (5)
- First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors (2022) (4)
- Epithelial Ovarian Cancer (2012) (4)
- SOCQER-2 Study: Preliminary analysis of multicentre recruitment after surgery in advanced ovarian cancer (2016) (4)
- Author response: La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs (2017) (4)
- Abstract CT028: First-in-human phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanisms (2016) (4)
- 805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment (2020) (4)
- ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF 11C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGING. (2015) (3)
- Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells (2021) (3)
- Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. (2018) (3)
- Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer. (2016) (3)
- Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors (2005) (3)
- Loss of LARP4B , an early event in the tumorigenesis of brain cancer? (2016) (3)
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial (2022) (3)
- Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient. (2013) (3)
- 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors (2012) (3)
- The perfect arrangement. (2014) (2)
- Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients (2018) (2)
- 968PPRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer (2017) (2)
- 517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours (2021) (2)
- Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer (2011) (2)
- NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer. (2019) (2)
- Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. (2005) (2)
- Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors (2017) (2)
- A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC) (2019) (2)
- 431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors (2008) (2)
- Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer (2008) (2)
- Obesity, physical inactivity and symptoms after ovarian cancer treatment: Results from an International internet-based survey (2015) (1)
- A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours. (2017) (1)
- Surgical and Medical Management of Epithelial Ovarian Cancer (2018) (1)
- A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies. (2018) (1)
- Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma (2019) (1)
- Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373:in vitroanalysis and clinical validation (2019) (1)
- A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer. (2016) (1)
- Abstract 3390: Validating the RNAscope for molecular profiling of key biomarkers associated with gemcitabine resistance (2015) (1)
- ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors (2014) (1)
- 464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study) (2020) (1)
- Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study (2018) (1)
- PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL (2022) (1)
- Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738 (2021) (1)
- 600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide:701) (2020) (1)
- A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302). (2021) (1)
- Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome (2022) (1)
- Targeting MAPK in recurrent, low-grade serous ovarian cancer (2022) (1)
- Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells (2017) (1)
- Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target (2017) (1)
- Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer (2012) (1)
- 354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302) (2022) (1)
- Increased persistence of treosulfan-induced DNA interstrand crosslinks when combined with gemcitabine: Proof of principle within a phase I trial (2003) (0)
- OUTCOMES IN MUCINOUS OVARIAN CARCINOMAS: 10 YEARS OF EXPERIENCE IN A TERTIARY CENTRE (2013) (0)
- A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. (2022) (0)
- CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials (2022) (0)
- 850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies (2022) (0)
- P11.06: Could LARP1 be a driving force in ovarian cancer transformation? (2017) (0)
- OVPSYCH2: A randomised study of psychological support following chemotherapy for ovarian cancer (2019) (0)
- Meteor-a Novel Gene Involved in Centrosome Function (2003) (0)
- Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent. (2019) (0)
- Referee acknowledgement for 2020 (2021) (0)
- Referee Acknowledgement for 2013 (2014) (0)
- Abstract 5962: NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients (2023) (0)
- Abstract B51: Management of ascites via the alfa-pump closed system in platinum-resistant-ovarian-cancer (PROC): A model of sequential non-invasive tumor-cell sampling through the urinary bladder (2013) (0)
- P-34 Who assesses performance status more accurately, patients or their oncologists? (2003) (0)
- 566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701) (2021) (0)
- Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer (2021) (0)
- Quality of Life with weekly platinum-based chemotherapy in newly diagnosed Ovarian Cancer: the ICON8 phase III randomised controlled clinical trial (2020) (0)
- Study to compare tolerability of standard versus modified mayo regimen 5-fluorouracil (2001) (0)
- Early stage mucinous ovarian carcinomas: 10 years of experience in a tertiary centre (2013) (0)
- Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement (2020) (0)
- Recurrent ovarian cancer (2015) (0)
- Abstract CT136: NUC-7738, a novel ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumors (2021) (0)
- Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. (2023) (0)
- With Thanks to the International Journal of Gynecological Cancer: Reviewers of 2011 (2011) (0)
- Referee acknowledgement for 2019 (2020) (0)
- 475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302) (2021) (0)
- A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol (2020) (0)
- 777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies (2022) (0)
- A Phase 1 dose escalation study of the pharmacokinetics and tolerability of ZK 304709 , an oral multi-targeted growth inhibitor ( MTGI TM ) , in patients with advanced solid tumours (2009) (0)
- Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism. (2019) (0)
- A decade of LARP society (2021) (0)
- 549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301) (2021) (0)
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer (2021) (0)
- A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. (2023) (0)
- 81 MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells (2012) (0)
- AUC 2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol , a sensitizer of platinum cytotoxicity : the phase III OVATUREmulticenter randomized study (2013) (0)
- Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials (2012) (0)
- A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer (2021) (0)
- LARP1 regulates metabolism and mTORC1 activity in cancer (2022) (0)
- PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials. (2022) (0)
- Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade (2023) (0)
- A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies. (2018) (0)
- Outcome in patients who become pregnant within 12 months after completing single and multiple agent chemotherapy for gestational trophoblastic disease (gtd) (1999) (0)
- A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours (2019) (0)
- Referee Acknowledgement for 2016 (2017) (0)
- Abstract A062: Preclinical study of the fungal derivative cordycepin as an anti-cancer agent (2019) (0)
- A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701). (2019) (0)
- From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. (2023) (0)
- The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5 (cid:2) TOP sequence (2015) (0)
- Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective (2022) (0)
- Feasibility of Trials in Ovarian Cancer by Line of Therapy and Platinum Sensitivity (2013) (0)
- Sustained platelet-sparing thromboprotective effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer (2011) (0)
- RNA: Reviewers for Volume 21, 2015. (2015) (0)
- Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials. (2012) (0)
- Abstract 572: Genome-scale CRISPR/Cas9 screen identifies factors required for sensitivity to pyrimidine nucleoside analogs (2018) (0)
- 315 LARP1 Regulates the Site-specific Synthesis of Proteins Required for Cancer Cell Invasion and Migration (2012) (0)
- OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer. (2021) (0)
- Molecular targets in ovarian cancer (2011) (0)
- Patterns of relapse in patients treated with surgery followed by platinum based chemotherapy for advanced epithelial ovarian cancer (2008) (0)
- Abstract B44: Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells (2017) (0)
- 116: The mRNA-binding protein LARP1 is a pro-survival factor that promotes tumourigenicity and chemotherapy resistance in ovarian cancer (2014) (0)
- OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer. (2018) (0)
- 455MO NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study (2022) (0)
- Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors (2023) (0)
- NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer. (2020) (0)
- NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment. (2018) (0)
This paper list is powered by the following services:
Other Resources About Sarah Blagden
What Schools Are Affiliated With Sarah Blagden?
Sarah Blagden is affiliated with the following schools:
